Publications by authors named "Argiris Symeonidis"

Claim this Profile
I
Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry.
Bente Houtman, Adele Taylor, Corine Van Marrewijk, Alexandra Smith, Pierre Fenaux, Argiris Symeonidis

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracellular Mis-Localization of Modified RNA Molecules and Non-Coding RNAs: Facts from Hematologic Malignancies.
Argiris Symeonidis, Argyri Chroni, Irene Dereki, Dionysios Chartoumpekis, Argyro Sgourou

Curr Issues Mol Biol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kimura's Disease: A Case Report.
Karolina Akinosoglou, Stamatia Tsoupra, Aggelos Rigopoulos, Georgios Schinas, Eleni Polyzou, Argiris Symeonidis

Cureus· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients.
Anthi Bouchla, Sotirios G Papageorgiou, Ioannis Kotsianidis, Panagiotis Diamantopoulos, Eleni Gavriilaki, Argiris Symeonidis

Br J Haematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Transcription Axes ERK-Elk1, JNK-cJun, and JAK-STAT Promote Autophagy Activation and Proteasome Inhibitor Resistance in Prostate Cancer Cells.
Georgios Kalampounias, Kalliopi Zafeiropoulou, Theodosia Androutsopoulou, Spyridon Alexis, Argiris Symeonidis

Curr Issues Mol Biol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).
Argiris Symeonidis, Panagiotis Diamantopoulos, Athanasios Galanopoulos, Alexandra Kourakli, Eleni Sazakli

Cancers (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study.
Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, Hsin-An Hou, Grzegorz Helbig, Argiris Symeonidis

Blood Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification.
Stavroula Syriopoulou, Christina-Nefeli Kontandreopoulou, Panagiotis T Diamantopoulos, Dimitra Vlachopoulou, Christos Stafylidis, Argiris Symeonidis

Leuk Lymphoma· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study.
Hege Kristin Gravdahl Garelius, Timothy Bagguley, Adele Taylor, Pierre Fenaux, David Bowen, Argiris Symeonidis

Lancet Haematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating advanced analytical methods to assess epigenetic marks affecting response to hypomethylating agents in higher risk myelodysplastic syndrome.
Theodoros Nikolopoulos, Eleftherios Bochalis, Theodora Chatzilygeroudi, Vasiliki Chondrou, Irene Dereki, Argiris Symeonidis

Mol Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: MDS: new scientific and clinical developments.
Sabine Blum, Argiris Symeonidis, Ulrich Germing

Front Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes.
David Rombaut, Sarah Sandmann, Tobias Tekath, Simon Crouch, Aniek O de Graaf, Argiris Symeonidis

Hemasphere· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients.
Eva Plakoula, Georgios Kalampounias, Spyridon Alexis, Evgenia Verigou, Alexandra Kourakli, Argiris Symeonidis

Curr Issues Mol Biol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi-center analysis of 719 disease episodes.
Jeremy W Jacobs, Caroline G Stanek, Garrett S Booth, Argiris Symeonidis, Andrew W Shih

Am J Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunophenotyping myelodysplastic neoplasms: the role of flow cytometry in the molecular classification era.
Evgenia Verigou, Theodora Chatzilygeroudi, Vasileios Lazaris, Anne-Lise de Lastic, Argiris Symeonidis

Front Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory profile of lower risk myelodysplastic syndromes.
Joanne Topping, Adele Taylor, Fatima Nadat, Simon Crouch, Alice Ibbotson, Argiris Symeonidis

Br J Haematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
Sosana Delimpasi, Meletios A Dimopoulos, Jan Straub, Argiris Symeonidis, Luděk Pour

Am J Hematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML.
Theodora Chatzilygeroudi, Vasiliki Chondrou, Ruben Boers, Stavroula Siamoglou, Katerina Athanasopoulou, Argiris Symeonidis

Clin Epigenetics· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
Matteo Sarocchi, Junmin Li, Xiao Li, Depei Wu, Efreen Montaño Figueroa, Argiris Symeonidis

Br J Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Francesco Onida, Nico Gagelmann, Yves Chalandon, Guido Kobbe, Marie Robin, Argiris Symeonidis

Blood· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delayed diagnosis of a primary diffuse large B-cell lymphoma of the humeral head, presenting as pathological fracture: a case report and review of the literature.
Andreas Panagopoulos, Konstantina Solou, Argiris Symeonidis, Evgenia Verigou, Olga Kouroukli

JSES Rev Rep Tech· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and -Mediated Immune Dysregulation Syndrome in Greece.
Androniki Kapousouzi, Fani Kalala, Styliani Sarrou, Evangelia Farmaki, Nikolaos Antonakos, Argiris Symeonidis

Medicina (Kaunas)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Argiris Symeonidis

Am J Hematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
Kalliopi Zafeiropoulou, Georgios Kalampounias, Spyridon Alexis, Daniil Anastasopoulos, Argiris Symeonidis

PLoS One· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece.
Theodora Chatzilygeroudi, Ismini Darmani, Natali El Gkotmi, Pinelopi Vryttia, Stavroula Douna, Argiris Symeonidis

J Clin Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis